Cabell Christopher 4
4 · Inhibikase Therapeutics, Inc. · Filed Feb 25, 2025
Insider Transaction Report
Form 4
Cabell Christopher
President & Head of R&D
Transactions
- Award
Stock Option (Right to Buy)
2025-02-21+1,100,705→ 1,100,705 totalExercise: $2.23Exp: 2035-02-21→ Common Stock (1,100,705 underlying)
Footnotes (1)
- [F1]The options will vest in three substantially equal installments on the second, third and fourth anniversaries of February 21, 2025, subject to the Reporting Person's continued services through such date.